Thienopyrimidines of the formula I
##STR1##
and their physiologically acceptable salts,
in which
R.sup.1, R.sup.2 and X have the meanings indicated in claim 1, exhibit
phosphodiesterase V inhibition and can be employed for the treatment of
disorders of the cardiovascular system and for the treatment and/or
therapy of potency disorders.
